1. Home
  2. KXIN vs PHGE Comparison

KXIN vs PHGE Comparison

Compare KXIN & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$6.49

Market Cap

9.7M

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$1.45

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
PHGE
Founded
2015
2015
Country
China
United States
Employees
13
57
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7M
9.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KXIN
PHGE
Price
$6.49
$1.45
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
15.9K
129.0K
Earning Date
11-26-2019
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$0.25
52 Week High
$22.00
$8.50

Technical Indicators

Market Signals
Indicator
KXIN
PHGE
Relative Strength Index (RSI) 63.94 23.47
Support Level $0.54 $0.42
Resistance Level $7.06 $2.35
Average True Range (ATR) 0.58 0.43
MACD -0.06 -0.14
Stochastic Oscillator 65.38 1.49

Price Performance

Historical Comparison
KXIN
PHGE

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: